Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study].

Cruz Jentoft AJ, Hernández B.

Neurologia. 2014 Jan-Feb;29(1):1-10. doi: 10.1016/j.nrl.2013.01.008. Epub 2013 Apr 10. Spanish.

2.

From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.

Reñé R, Ricart J, Hernández B; researchers in the Experience study.

Neurologia. 2014 Mar;29(2):86-93. doi: 10.1016/j.nrl.2013.02.012. Epub 2013 May 17. English, Spanish.

3.

Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.

Boada M, Arranz FJ.

Dement Geriatr Cogn Disord. 2013;35(1-2):23-33. doi: 10.1159/000345989. Epub 2013 Jan 9.

PMID:
23306147
4.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

6.
7.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
8.

Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.

Gauthier S, Robillard A, Cohen S, Black S, Sampalis J, Colizza D, de Takacsy F, Schecter R; EMBRACE investigators.

Curr Med Res Opin. 2013 Aug;29(8):989-1000. doi: 10.1185/03007995.2013.802230. Epub 2013 May 23.

PMID:
23647369
9.

Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?

Sevilla C, Jiménez Caballero PE, Alfonso V, González-Adalid M.

Dement Geriatr Cogn Disord. 2009;28(3):196-205. doi: 10.1159/000236015. Epub 2009 Sep 9.

PMID:
19738386
10.
11.

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO.

Dement Geriatr Cogn Disord. 2005;19(1):51-6. Epub 2004 Sep 21.

12.

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2005 Aug;21(8):1317-27.

PMID:
16083542
13.

Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.

Mets T, Vandewoude M, Jacquy J, Deblander A, MacDonald K, Sloesen A, Abraham I; FExT Study Group.

Curr Med Res Opin. 2007 Oct;23(10):2485-501.

PMID:
17784995
14.

[Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].

González-Gutiérrez JL, Gobartt AL; en representación del grupo de investigadores RIVASOL.

Rev Neurol. 2007 Jun 16-30;44(12):705-10. Spanish.

15.

Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.

Chiu PY, Dai DE, Hsu HP, Lee C, Lin JJ, Kuo HC, Huang YC, Liu YC, Tsai CP.

Clin Drug Investig. 2009;29(11):729-38. doi: 10.2165/11315320-000000000-00000.

PMID:
19813776
16.

Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).

Gauthier S, Juby A, Dalziel W, Réhel B, Schecter R; EXPLORE investigators.

Curr Med Res Opin. 2010 May;26(5):1149-60. doi: 10.1185/03007991003688888.

PMID:
20230208
17.

Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.

Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK.

Neurology. 2007 Jul 24;69(4 Suppl 1):S23-8.

PMID:
17646620
18.

A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.

Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A.

Int J Clin Pract. 2011 Jul;65(7):790-6. doi: 10.1111/j.1742-1241.2011.02713.x. Epub 2011 Jun 6.

PMID:
21645184
19.

A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.

Gauthier S, Juby A, Morelli L, Rehel B, Schecter R; EXTEND Investigators.

Curr Med Res Opin. 2006 Nov;22(11):2251-65.

PMID:
17076986
20.

Discontinuation of rivastigmine in routine clinical practice.

Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JP, Koks CH, Beijnen JH.

Int J Geriatr Psychiatry. 2005 Dec;20(12):1167-71.

PMID:
16315150

Supplemental Content

Support Center